CRISPR

YTD

ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA.

CEO

Samarth Kulkarni

CEOSamarth Kulkarni

Employees

393

Employees393

Headquarters

Zug, Zug

HeadquartersZug, Zug

Founded

2013

Founded2013

Employees

393

Employees393

CRSP Key Statistics

Market cap

4.92B

Market cap4.92B

Price-Earnings ratio

-8.95

Price-Earnings ratio-8.95

Dividend yield

—

Dividend yield—

Average volume

1.83M

Average volume1.83M

High today

$51.90

High today$51.90

Low today

$48.60

Low today$48.60

Open price

$49.53

Open price$49.53

Volume

928.86K

Volume928.86K

52 Week high

$78.48

52 Week high$78.48

52 Week low

$30.04

52 Week low$30.04

Stock Snapshot

The current CRISPR(CRSP) stock price is $51.66, with a market capitalization of 4.92B. The stock trades at a price-to-earnings (P/E) ratio of -8.95.

On 2026-02-02, CRISPR(CRSP) stock moved within a range of $48.60 to $51.90. With shares now at $51.66, the stock is trading +6.3% above its intraday low and -0.5% below the session's peak.

Trading volume for CRISPR(CRSP) stock has reached 928.86K, versus its average volume of 1.83M.

The stock's 52-week range extends from a low of $30.04 to a high of $78.48.

CRSP News

TipRanks 3d

Cathie Wood Buys the Dip in Joby Aviation, Sells Teradyne Near Highs

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Thursday, January 29, as revealed in daily fund disclosures. These trades...

Simply Wall St 4d

CRISPR Therapeutics CEO Share Sale Tests Confidence In Gene Editing Story

CRISPR Therapeutics (NasdaqGM:CRSP) CEO Samarth Kulkarni has executed a significant insider sale of company shares. The transaction involved a substantial port...

TipRanks 6d

Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy

New insider activity at Crispr Therapeutics AG ( (CRSP) ) has taken place on January 27, 2026. CMO Naimish Patel of Crispr Therapeutics AG recently purchased 1...

Analyst ratings

59%

of 29 ratings

Buy

58.6%

Hold

37.9%

Sell

3.4%

More CRSP News

Benzinga 6d

Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP) , has come under renewed pressure in recent weeks, amid insider sales, slow revenue g...

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Intellia Therapeutics

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.